Literature DB >> 34070953

2-[18F]FDG PET/CT as a Predictor of Microvascular Invasion and High Histological Grade in Patients with Hepatocellular Carcinoma.

Aida Sabaté-Llobera1,2, Judit Mestres-Martí1,2, Gabriel Reynés-Llompart1,2,3,4, Laura Lladó2,4,5, Kristel Mils2,5, Teresa Serrano2,6,7, Montserrat Cortés-Romera1,2,4, Esther Bertran7,8, Isabel Fabregat2,7,8, Emilio Ramos2,4,5,7.   

Abstract

Hepatocellular carcinoma (HCC) generally presents a low avidity for 2-deoxy-2-[18F]fluoro-d-glucose (FDG) in PET/CT although an increased FDG uptake seems to relate to more aggressive biological factors. To define the prognostic value of PET/CT with FDG in patients with an HCC scheduled for a tumor resection, forty-one patients were prospectively studied. The histological factors of a poor prognosis were determined and FDG uptake in the HCC lesions was analyzed semi-quantitatively (lean body mass-corrected standardized uptake value (SUL) and tumor-to-liver ratio (TLR) at different time points). The PET metabolic parameters were related to the histological characteristics of the resected tumors and to the evolution of patients. Microvascular invasion (MVI) and a poor grade of differentiation were significantly related to a worse prognosis. The SULpeak of the lesion 60 min post-FDG injection was the best parameter to predict MVI while the SULpeak of the TLR at 60 min was better for a poor differentiation. Moreover, the latter parameter was also the best preoperative variable available to predict any of these two histological factors. Patients with an increased TLRpeak60 presented a significantly higher incidence of poor prognostic factors than the rest (75% vs. 28.6%, p = 0.005) and a significantly higher incidence of recurrence at 12 months (38% vs. 0%, p = 0.014). Therefore, a semi-quantitative analysis of certain metabolic parameters on PET/CT can help identify, preoperatively, patients with histological factors of a poor prognosis, allowing an adjustment of the therapeutic strategy for those patients with a higher risk of an early recurrence.

Entities:  

Keywords:  2-[18F]FDG; PET/CT; cellular differentiation.; hepatocellular carcinoma; lean body mass; liver resection; microvascular invasion; standardized uptake value

Year:  2021        PMID: 34070953     DOI: 10.3390/cancers13112554

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  31 in total

1.  Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose.

Authors:  B M Gallagher; J S Fowler; N I Gutterson; R R MacGregor; C N Wan; A P Wolf
Journal:  J Nucl Med       Date:  1978-10       Impact factor: 10.057

2.  18F-FDG PET/CT predicts microvascular invasion and early recurrence after liver resection for hepatocellular carcinoma: A prospective observational study.

Authors:  Chetana Lim; Chady Salloum; Julia Chalaye; Eylon Lahat; Charlotte E Costentin; Michael Osseis; Emmanuel Itti; Cyrille Feray; Daniel Azoulay
Journal:  HPB (Oxford)       Date:  2018-11-03       Impact factor: 3.647

3.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

4.  Prediction of microvascular invasion of hepatocellular carcinoma: preoperative CT and histopathologic correlation.

Authors:  Chen-Te Chou; Ran-Chou Chen; Wei-Chan Lin; Chih-Jan Ko; Chia-Bang Chen; Yao-Li Chen
Journal:  AJR Am J Roentgenol       Date:  2014-09       Impact factor: 3.959

Review 5.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

Review 6.  Prognostic factors for hepatocellular carcinoma recurrence.

Authors:  Antonio Colecchia; Ramona Schiumerini; Alessandro Cucchetti; Matteo Cescon; Martina Taddia; Giovanni Marasco; Davide Festi
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

7.  Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection.

Authors:  Joana Ferrer-Fàbrega; Alejandro Forner; Alexandre Liccioni; Rosa Miquel; Víctor Molina; Miquel Navasa; Constantino Fondevila; Juan Carlos García-Valdecasas; Jordi Bruix; Josep Fuster
Journal:  Hepatology       Date:  2016-01-13       Impact factor: 17.425

8.  In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.

Authors:  T Torizuka; N Tamaki; T Inokuma; Y Magata; S Sasayama; Y Yonekura; A Tanaka; Y Yamaoka; K Yamamoto; J Konishi
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

9.  Clinical usefulness of FDG-PET in patients with hepatocellular carcinoma undergoing surgical resection.

Authors:  Kyung Jin Cho; Nam Kyu Choi; Min Ho Shin; A Ri Chong
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2017-11-30

Review 10.  Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma.

Authors:  Sang Mi Lee; Hong Soo Kim; Sangheun Lee; Jeong Won Lee
Journal:  World J Gastroenterol       Date:  2019-03-21       Impact factor: 5.742

View more
  1 in total

Review 1.  18F-FDG /18F-Choline Dual-Tracer PET Behavior and Tumor Differentiation in HepatoCellular Carcinoma. A Systematic Review.

Authors:  Jérôme Ghidaglia; Nicolas Golse; Alina Pascale; Mylène Sebagh; Florent L Besson
Journal:  Front Med (Lausanne)       Date:  2022-07-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.